
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Franklin Genomic Advancements ETF (BATS:HELX) through any online brokerage.
There are no as such competitors for Franklin Genomic Advancements ETF.
There is no analysis for Franklin Genomic Advancements ETF to provide a consensus price target.
The stock price for Franklin Genomic Advancements ETF (BATS: HELX) is $31.9831 last updated March 13, 2026 at 8:00 PM EDT.
There are no upcoming dividends for Franklin Genomic Advancements ETF.
Franklin Genomic Advancements ETF does not have any upcoming earnings scheduled.
There is no upcoming split for Franklin Genomic Advancements ETF.
| Sector | Healthcare |
| Category | High Performer-High Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Feb 25, 2020 |
| Managers | Matthew J. Moberg |
| Definition | An equity fund portfolio full of stocks with both strong financial performance and superior growth potential |
| Symbol | Name | Share % |
|---|---|---|
| MEDP | Medpace Holdings Inc | 4.47% |
| KRYS | Krystal Biotech Inc | 5.11% |
| NTRA | Natera Inc | 6.31% |
| UTHR | United Therapeutics Co... | 3.49% |
| ALNY | Alnylam Pharmaceutical... | 3.25% |
| GH | Guardant Health Inc | 7.17% |
| INSM | Insmed Inc | 3.89% |
| ADPT | Adaptive Biotechnologi... | 3.59% |
| BBIO | Bridgebio Pharma Inc | 3.94% |
| KR | Samsung Biologics Co L... | 3.40% |
Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API
Market data provided by Benzinga APIs